Laurus Labs, as per the policy of the Government for captive consumption of power, has entered into Share Subscription agreement and Shareholders’ agreement on November 23, 2022 with Ethan Energy India for subscribing 7,40,000 Equity Shares of face value of Rs 10 each at a premium of Rs 42.70 which is equivalent to 26% of the paid up capital of Ethan Energy India. This will enable the Company to consume 100% of the solar energy to be supplied by Ethan Energy India from their 10 MW Solar Energy plant.
Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
